- Home
- ANVS vs NRXP Comparison
ANVS vs NRXP Comparison
Compare ANVS & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANVS | NRXP |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.3M | 73.7M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANVS | NRXP |
|---|---|---|
| Price | $4.54 | $2.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $13.50 | ★ $30.50 |
| AVG Volume (30 Days) | ★ 3.9M | 446.3K |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $242,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $643.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $1.15 |
| 52 Week High | $6.37 | $6.01 |
Technical Indicators
Market Signals| Indicator | ANVS | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 68.85 | 45.23 |
| Support Level | $4.01 | $2.22 |
| Resistance Level | $4.82 | $2.51 |
| Average True Range (ATR) | 0.66 | 0.19 |
| MACD | 0.06 | 0.04 |
| Stochastic Oscillator | 69.78 | 68.52 |
Price Performance
Historical ComparisonAbout ANVS Annovis Bio Inc.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.